DOI: 10.1055/s-00000054

Pharmacopsychiatry

Issue 03 · Volume 40 · May 2007 DOI: 10.1055/s-002-6772

Original Paper

89
Mauri, M. C.; Colasanti, A.; Rossattini, M.; Volonteri, L. S.; Dragogna, F.; Fiorentini, A.; Valli, A.; Papa, P.: Ziprasidone Outcome and Tolerability: A Practical Clinical Trial With Plasma Drug Levels
111
Stolk, P.; Souverein, P. C.; Leufkens, H. G. M.; Weil, J. G.; Egberts, A. C. G.; Heerdink, E. R.: The Association between Exposure to COX-2 Inhibitors and Schizophrenia Deterioration. A Nested Case-Control Study
121
Ulrich, S.; Hiemke, C.; Laux, G.; Müller-Oerlinghausen, B.; Havemann-Reinecke, U.; Riederer, P.; Zernig, G.; Baumann, P.; TDM group of the Arbeitsgemeinschaft Neuropsychopharmakologie und Pharmakopsychiatrie (AGNP): Value and Actuality of the Prescription Information for Therapeutic Drug Monitoring of Psychopharmaceuticals: A Comparison with the Medico-Scientific Evidence

Letter

128
Bachmann, C.; Grabarkiewicz, J.; Theisen, F. M.; Remschmidt, H.: Isotretinoin, Depression and Suicide Ideation in an Adolescent Boy
132
Habermeyer, B.; Fuhr, P.: Authors' Reply

Erratum